Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew

  • Raymond James initiated coverage on Avidity Biosciences Inc RNA with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc DYN with an Outperform rating and $15 price target (68% upside). 
  • The analysts bet on the targeted delivery of oligonucleotides improving the therapeutic window of first-generation oligonucleotides.
  • Related: Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle Wasting Disorder.
  • The rating is bent towards Avidity based on more near-term clinical data (4Q22, whereas Dyne is beginning dosing in mid-2022), and preclinical data packages share similarities, but muscle tissue delivery seems slightly more evident for Avidity. 
  • Also See: Dyne's Shares Gain After FDA Removed Clinical Hold On Muscular Disease Study.
  • Using Sarepta Therapeutics Inc's SRPT success and launch trajectory in the DMD market as a surrogate for launch assumptions, Raymond James models Avidity launching in 2026 and capturing 40% of the DM1 market at peak, with ~80% total addressable patients.
  • For Dyne, the analyst anticipates a launch in 2027 and 35% at peak, corresponding to peak DM1 sales of $2.4 billion for Avidity and $2.1 billion for Dyne.
  • Price Action: DYN stock is up 3.96% at $8.92, and RNA shares are up 5.63% at $17.25 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!